We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ekf Diagnostics Holdings Plc | LSE:EKF | London | Ordinary Share | GB0031509804 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.65 | 2.19% | 30.30 | 30.00 | 30.60 | 30.70 | 30.00 | 30.70 | 245,917 | 16:35:02 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Med, Dental, Hosp Eq-whsl | 52.61M | 2.35M | 0.0052 | 57.69 | 136.48M |
From May 2019 to May 2024
TIDMEKF
RNS Number : 5336B
EKF Diagnostics Holdings PLC
11 January 2018
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).
EKF Diagnostics Holdings plc
("EKF", the "Company")
Trading update
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, provides shareholders with the following update on current trading.
The Company is pleased to announce that revenues for the year ended 31 December 2017 are in line with expectations whilst adjusted EBITDA is expected to comfortably exceed expectations. Net cash at the year end is GBP6.8m.
The Company also announces that it intends to spin-out its sTNFR biomarker technology into a separate entity to enable it to exploit opportunities to realise value from this technology, which having been fully impaired and has a current carrying value of nil. sTNFR1/2 (Soluble Tumour Necrosis Factor Receptors 1 and 2) are novel biomarkers used to identify type 1 and type 2 diabetes patients at highest risk of progressive Diabetic Kidney Disease (DKD) potentially leading to End Stage Renal Disease (ESRD).
The Directors intend to establish a joint venture to develop sTNFR as a routine test for predicting the progression of diabetic patients to ESRD and will make further announcements at the appropriate time.
Enquiries:
EKF Diagnostics Holdings plc www.ekfdiagnostics.com Christopher Mills, Non-Executive Tel: 029 2071 0570 Chairman Julian Baines, CEO Richard Evans, FD & COO N+1 Singer (Nomad & Broker) Tel: 020 7496 3000 Alex Price / Shaun Dobson / Ali Laughton-Scott Walbrook PR Limited Tel: 020 7933 8780 or ekf@walbrookpr.com Paul McManus / Lianne Cawthorne Mob: 07980 541 893 / 07584 391 303
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTLLFSRLDIILIT
(END) Dow Jones Newswires
January 11, 2018 02:00 ET (07:00 GMT)
1 Year Ekf Diagnostics Chart |
1 Month Ekf Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
